Celgene: A Promising Stock
With an attractive balance sheet, healthy revenue growth and a solid return on equity, biotech company Celgene looks like a promising stock buy.
Merck Co
Confirmed: Why Merck Halted Its Stroke-Victim Study
When Merck halted a late-stage study of its potential clot-preventing drug vorapaxar in stroke victims last week, it didn't explain why. Now, the company has confirmed it stopped the study after concerns that the drug increased the risk of bleeding in some patients.